We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

AXP:NYSEAmerican Express Company Analysis

Data as of 2026-06-08 - not real-time

$313.64

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

American Express is trading at $313.64, comfortably below its 20‑day (≈$311.6) and 50‑day (≈$314.7) simple moving averages and well under the 200‑day SMA (≈$337), signaling a short‑term bearish bias. The RSI sits around 50, indicating neutral momentum, while the MACD histogram has turned positive, offering a modest bullish hint. Volatility over the past 30 days is high at roughly 22% and beta exceeds 1.0, suggesting the stock is more sensitive to market swings; the max drawdown of about 24% underscores recent downside risk. Despite these technical pressures, the DCF‑derived fair value of ≈$375.5 implies roughly 15% upside, and the Fear & Greed Index reads “Extreme Greed,” reflecting strong market appetite.
Fundamentally, AXP delivers robust growth with revenue up 11.6% year‑over‑year, gross margins above 62% and an impressive ROE of 34%, positioning it as a high‑quality growth‑value hybrid. The dividend yield of 1.22% is supported by a low payout ratio (~21%), and the balance sheet holds over $53 bn in cash against $60 bn of debt, yielding a manageable leverage profile. Recent material events—selling its remaining stake in GBTG for $1.5 bn, a new quarterly dividend declaration, and Loop Capital’s fresh buy coverage—reinforce cash generation and investor confidence. Berkshire Hathaway’s multi‑decade stake adds a strong endorsement, suggesting the stock remains a long‑term value play despite the recent double‑digit price decline.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below short‑term SMAs indicating bearish pressure
  • Positive MACD histogram offering limited upside
  • Stable dividend with low payout ratio

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF‑based upside of ~15% and price below fair value
  • Strong revenue growth and high ROE
  • Cash inflow from GBTG stake sale and supportive analyst coverage

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Durable brand and franchise with global diversification
  • Consistent profitability and high margins
  • Long‑term endorsement from Berkshire Hathaway and sustainable dividend

Key Metrics & Analysis

Financial Health

Revenue Growth11.60%
Profit Margin16.30%
P/E Ratio19.6
ROE34.42%
ROA3.80%
Debt/Equity177.85
P/B Ratio6.3
Op. Cash Flow$17.5B
Industry P/E17.0

Technical Analysis

TrendBearish
RSI50.7
Support$300.03
Resistance$319.24
MA 20$311.61
MA 50$314.67
MA 200$337.16
MACDBullish
VolumeStable
Fear & Greed Index88.27

Valuation

Fair Value$375.50
Target Price$361.57
Upside/Downside15.28%
GradeUndervalued
TypeBlend
Dividend Yield1.22%

Risk Assessment

Beta1.09
Volatility21.55%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.